Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 6302
TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 83nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataIC50: 180nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8722895, 20: {[5-(3-Cyanophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 190nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 240nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataIC50: 300nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 300nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US8722895, 12: {[5-(2-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 390nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 390nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107718(US8722895, 24: ({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)...)
Affinity DataIC50: 400nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 410nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataIC50: 440nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107702(US8722895, 8: {[5-(4-Cyanophenyl)-3-hydroxypyridin...)
Affinity DataIC50: 560nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataIC50: 650nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US8722895, 12: {[5-(2-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 1.10E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 1.10E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataIC50: 1.20E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataIC50: 1.30E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataIC50: 1.60E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataIC50: 2.50E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataIC50: 2.50E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107713(US8722895, 19: ({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)...)
Affinity DataIC50: 2.60E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 3.70E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107712(US8722895, 18: {[5-(3-Cyano-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 5.10E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107697(US8722895, 3: {[5-(4-Cyano-phenyl)-3-hydroxy-pyrid...)
Affinity DataIC50: 5.80E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 6.80E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataIC50: 1.12E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4...)
Affinity DataIC50: 2.00E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.14E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 3.75E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 5.23E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107702(US8722895, 8: {[5-(4-Cyanophenyl)-3-hydroxypyridin...)
Affinity DataIC50: 9.90E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent